[Meta-analysis of alendronate preventing hip fracture risk of postmenopausal women].
OBJECTIVE
To study the efficacy of alendronate to prevent hip fracture risk of postmenopausal women.


METHODS
Randomized controlled trials in postmenopausal women receiving alendronate or placebo for preventing hip fractures rate were searched from Medline, EMBASE, Cochrane Trial Registry and China Biological Medicine database between January 1980 to December 2007. Key words included hip fractures, alendronate, postmenopausal and placebo-controlled. Language was limited in English and Chinese. The software Revman 4.2 was used to perform meta-analysis.


RESULTS
Six trials, which included 8610 postmenopausal women, met all our inclusion criteria Meta-analysis showed that alendronate can decrease hip fracture rate (OR = 0.51, 95% CI: 0.34, 0.77).


CONCLUSIONS
Alendronate can reduce significantly hip fracture rate in postmenopausal women.
Yuan
Ting
T
Orthopedic Department, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China. terrence_yuan@yahoo.com.cn
Li
Xiao-lin
XL
Zhang
Chang-qing
CQ
Shi
Hui-peng
HP
Zeng
Bing-fang
BF
D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control*; D006801:Humans; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D019386:Alendronate